RT Journal Article
SR Electronic
T1 Clinical characteristics and early outcomes in patients with COVID-19 treated with tocilizumab at a United States academic center
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.13.20100404
DO 10.1101/2020.05.13.20100404
A1 Rimland, Casey A.
A1 Morgan, Camille E.
A1 Bell, Griffin J.
A1 Kim, Min K.
A1 Hedrick, Tanner
A1 Marx, Ashley
A1 Bramson, Brian
A1 Napravnik, Sonia
A1 Schmitz, John L.
A1 Carson, Shannon S.
A1 Fischer, William A.
A1 Eron, Joseph J.
A1 Gay, Cynthia L.
A1 Parr, Jonathan B.
YR 2020
UL http://medrxiv.org/content/early/2020/05/19/2020.05.13.20100404.abstract
AB Limited evidence is available to guide treatment of coronavirus disease 2019 (COVID-19), caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A hyperinflammatory state mediated by interleukin-6 (IL-6) has been proposed as a driver of severe disease. Use of the IL-6 receptor inhibitor tocilizumab for severe COVID-19 was first reported in China, where a case series described marked improvements in inflammatory markers, fever, oxygen requirement, and outcomes following its administration. Here, we provide the first description of a tocilizumab-treated cohort of patients with COVID-19 in the United States. We describe 11 patients from a single academic medical center, nine (82%) of whom were critically ill requiring mechanical ventilation in an intensive care unit at the time of tocilizumab administration. C-reactive protein levels decreased in all patients following treatment (median 211.6 pre- vs. 19.7 mg/L 5 days post-tocilizumab [p = 0.001]). When IL-6 levels were obtained before and after therapy, wide variation was seen in baseline levels; post-dose IL-6 concentrations were consistently increased. In contrast to prior reports, we did not observe significant clinical improvement in temperature or oxygen requirements in most patients. Two patients were discharged (18%), five remained in critical condition in the intensive care unit (46%), one was weaned off the ventilator to room air (9%), and three died (27%). Our findings suggest that tocilizumab should be used with caution in severe and critically ill patients and highlight the need for data from randomized controlled trials to determine its efficacy in the treatment of COVID-19.Competing Interest Statement JBP reports research support outside the submitted work from Gilead Sciences and the World Health Organization, and non-financial support from Abbott Laboratories. CLG has received research support outside the submitted work from Viiv Healthcare and Gilead Sciences. SSC reports research support outside of the submitted work from Biomarck Pharmaceuticals.Funding StatementThe authors report no designated funding for the project. CAR and CEM receive training support from the University of North Carolina at Chapel Hill Medical Scientist Training Program. CAR additionally receives training support from the National Institutes of Health MD/PhD Partnership Program.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available on request.